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Focus Issue: PROVE IT-TIMI 22
Implications of the PROVE IT-TIMI 22 Trial
The PROVE IT-TIMI 22 trial randomized over 4,000 subjects with acute coro-nary syndromes (ACS) to either moderate (average low-density lipoprotein
[LDL] 62 mg/dl) or intensive (average LDL 95 mg/dl) lipid lowering. Intensive
therapy was superior to moderate with a 16% reduction in the primary endpoint. This
trial provides strong support for the “lower is better” theory of lipid modification; the
robust dataset enable the four papers in this focus issue to examine why. Ray and
colleagues examined the timing of the benefit seen in PROVE IT-TIMI 22 trial. They
found a relative risk reduction of nearly 30% in both the first 30 days and 6 months
after an ACS, suggesting that intensive statin therapy provides “two windows of
cardioprotection” and should begin in-hospital and continue for the long term.
Wiviott and colleagues examined the safety of extremely low LDL by determining the
rates of adverse events stratified by LDL levels, including the 10% of subjects who had
LDLs40 mg/dl. No relationship was found between achieved LDL level and either
statin side effects or adverse events postulated to be secondary to low cholesterol. The
benefits, however, continued to improve with these very low LDL levels. Another paper
by Ray and colleagues focuses on the relationship between C-reactive protein (CRP)
and intensive lipid lowering. Several metabolic and lifestyle risk factors were associated
with higher CRP levels, such that CRP was found to be a “global barometer” of
cardiovascular risk. In a final paper, Ray and Cannon discuss the evidence that statins
exert a beneficial effect that is disproportionate to the LDL reduction: supporting the
benefits of pleiotropic effects. See pages 1405, 1411, 1417, and 1425. See
figures.
Simon Dack Lecture
Identifying Genetic Risk Factors for Myocardial Infarction
At the 2005 ACC conference, Dr. Eric Topol delivered the keynote Simon DackLecture. This reprint of his address explores the past, present, and future of the
ability of genomic techniques to identify heritable factors that predispose to myocardial
infarctions. The speech can serve as a primer to the techniques used to identify
suspected genes as it guides us through the recent breakthroughs in genotyping
technology. He touches on several emerging sequencing techniques along with the
development of a core map of the genome that should speed the discovery process over
the next decade. He expresses hope that we are on the precipice of understanding these
genetic risk factors and eventually to individually tailored therapies.See page1456.
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Cardiac Surgery
Intraoperative Assessment of Coronary Bypass Grafts
A certain percentage of coronary artery bypass grafts occlude shortly after surgery.While neither the frequency nor the etiology is known, visualizing graft patency
intraoperatively might allow problems to be identified early and repaired. Desai and
colleagues describe a technique using fluorescent indocyanine green (ICG) dye to
visualize the recently implanted grafts and the native coronary vessels. ICG is thought
to be non-toxic; when excited with a laser light it emits a characteristic frequency of
light that can be visualized using a CCD. In 120 patients undergoing bypass surgery,
problems with a graft that required revision were found in 4% of patients despite
apparent success to the surgeons. This technique may allow for real time visualization
of bypass grafts and improvements in graft patency before leaving the operating room.
See page 1521. See figure.
Page 1544
Hypertrophic Cardiomyopathy
Frequency of Transition From Hypertrophic to Dilated Cardiomyopathy
That a certain percentage of patients with hypertrophic cardiomyopathy (HCM)will transition to a hypokinetic dilated cardiomyopathy (DCM) is known, but
poorly understood. Biagini and colleagues report that in a large cohort of HCM
patients followed for a mean of 12 years, the incidence of the transition is 5.3 per 1,000
patient-years. Those who had transitioned to DCM were younger and more likely to
have a family history of HCM, and more pronounced hypertrophy. Clinically, they
were more likely to die or require heart transplantation. Further understanding the
transition from HCM to DCM has important clinical and biologic ramifications.See
page 1543. See figure.
